Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Adenocarcinoma 10%
• Alectinib 10%
• Anaplastic Lymphoma Kinase 60%
• Anaplastic Lymphoma Kinase Inhibitor 40%
• Brigatinib 10%
• Ceritinib 10%
• Clinical Trial 20%
• Crizotinib 10%
• Echinoderm 10%
• Lung Cancer 20%
• Microtubule Associated Protein 10%
• Non Small Cell Lung Cancer 40%
• Protein Tyrosine Kinase Inhibitor 10%

Biochemistry, Genetics and Molecular Biology

• Anaplastic Lymphoma Kinase 100%
• Crizotinib 10%
• Development 20%
• Echinoderm 10%
• Genetics 10%
• Light 10%
• Microtubule-Associated Protein 10%
• Oncogene 10%
• Small Molecule 10%
• Smoking 10%